{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:54:50Z","timestamp":1721663690022},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1589,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1038\/ki.2011.142","type":"journal-article","created":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T12:37:04Z","timestamp":1306931824000},"page":"245-255","source":"Crossref","is-referenced-by-count":15,"title":["Combination inhibition of the renin\u2013angiotensin system: is more better?"],"prefix":"10.1016","volume":"80","author":[{"given":"Michelle W.","family":"Krause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2011.142_bb0010","first-page":"380","article-title":"Tubular view of the morbid appearances in 100 cases connected with albuminous urine: with observations","volume":"1","author":"Bright","year":"1836","journal-title":"Guy's Hops Rep"},{"key":"10.1038\/ki.2011.142_bb0015","first-page":"62","article-title":"The physiology and clinical use of the sphygmograph","volume":"1","author":"Mahomed","year":"1872","journal-title":"Med Times Gaz"},{"key":"10.1038\/ki.2011.142_bb0020","first-page":"981","article-title":"Un sfigmomanometro nuovo","volume":"47","author":"Riva-Rocci","year":"1896","journal-title":"Gazetta Medica di Torino"},{"key":"10.1038\/ki.2011.142_bb0025","first-page":"365","article-title":"On methods of studying blood pressure [in Russian]","volume":"11","author":"Korotkoff","year":"1905","journal-title":"Bull Imperial Mil Med Acad"},{"key":"10.1038\/ki.2011.142_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere Und Kreislauf","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skand Arch Physiol"},{"key":"10.1038\/ki.2011.142_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.59.3.347","article-title":"Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischaemia","volume":"59","author":"Goldblatt","year":"1934","journal-title":"J Exp Med"},{"key":"10.1038\/ki.2011.142_bb0040","series-title":"Bradykinin, Kallidin, and Kallikrein Handbook of Experimental Pharmacology","first-page":"1","article-title":"Discovery of the most important kallikreins and kallikrein inhibitors","author":"Werle","year":"1970"},{"key":"10.1038\/ki.2011.142_bb0045","first-page":"75","article-title":"La secretion de la renina y la formacion de hipertensina","volume":"16","author":"Leloir","year":"1940","journal-title":"Rev Soc Arg Biol"},{"key":"10.1038\/ki.2011.142_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3181\/00379727-39-10149P","article-title":"Activation of renin by blood colloids","volume":"39","author":"Kohlstaedt","year":"1938","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1038\/ki.2011.142_rf0055","series-title":"Biochemical Regulation of Blood Pressure","first-page":"3","article-title":"Experimental renal hypertension: the discovery of the renin-angiotensin system","author":"Skeggs","year":"1981"},{"key":"10.1038\/ki.2011.142_bb0060","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0002-8703(61)90265-4","article-title":"The renin-angiotensin system in hypertension","volume":"62","author":"Tacquini","year":"1961","journal-title":"Am Heart J"},{"key":"10.1038\/ki.2011.142_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/225379a0","article-title":"Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme","volume":"225","author":"Ferreira","year":"1970","journal-title":"Nature"},{"key":"10.1038\/ki.2011.142_bb0070","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0024-3205(67)90090-2","article-title":"An enzyme in microsomal fraction of kidney that inactivates bradykinin","volume":"6","author":"Erd\u00f6s","year":"1967","journal-title":"Life Sci"},{"key":"10.1038\/ki.2011.142_bb0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0033-0620(78)90025-7","article-title":"Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients","volume":"21","author":"Case","year":"1978","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1038\/ki.2011.142_bb0080","first-page":"340","article-title":"Hypotensive imidazole derivatives","volume":"4","author":"Yoshiyasu","year":"1982","journal-title":"US Patent"},{"key":"10.1038\/ki.2011.142_bb0085","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1038\/ki.2011.142_bb0090","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","article-title":"The role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1038\/ki.2011.142_bb0095","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","article-title":"Comparative effects of AT-1 antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease","volume":"44","author":"Schieffer","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2011.142_bb0100","doi-asserted-by":"crossref","first-page":"25J","DOI":"10.1016\/j.amjcard.2007.05.011","article-title":"Rationale for double renin-angiotensin-aldosterone-system blockade","volume":"100","author":"Unger","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1038\/ki.2011.142_bb0105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension: renin and aldosterone, heart attack, and stroke","volume":"286","author":"Brunner","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200018080-00020","article-title":"Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients","volume":"18","author":"Azizi","year":"2000","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.142_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00005344-200006000-00017","article-title":"Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension","volume":"35","author":"Stergiou","year":"2000","journal-title":"Cardiovasc Pharmacol"},{"key":"10.1038\/ki.2011.142_bb0120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0895-7061(01)01296-1","article-title":"Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake","volume":"14","author":"Weir","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1038\/ki.2011.142_bb0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3317\/jraas.2004.012","article-title":"Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria","volume":"5","author":"Morgan","year":"2004","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1038\/ki.2011.142_bb0130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0895-7061(00)01304-2","article-title":"Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial","volume":"14","author":"Weir","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1038\/ki.2011.142_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00044011-199918060-00004","article-title":"Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs. Results of the AURA study","volume":"18","author":"Schulte","year":"1999","journal-title":"Clin Drug Invest"},{"key":"10.1038\/ki.2011.142_bb0140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1524-6175.2004.03511.x","article-title":"Antihypertensive efficacy of candesartan-lisinopril in combination vs up-titration of lisinopril: the AMAZE trials","volume":"6","author":"Izzo","year":"2004","journal-title":"J Clin Hypertens"},{"key":"10.1038\/ki.2011.142_bb0145","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.142_bb0150","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"The ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0155","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.107.093682","article-title":"Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction","volume":"51","author":"Thune","year":"2008","journal-title":"Hypertension"},{"key":"10.1038\/ki.2011.142_bb0165","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2008.10.036","article-title":"The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point","volume":"53","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2011.142_bb0170","series-title":"Guideline alert for blood pressure patients as treatment combo (press release)","author":"Heart and Stroke Foundation","year":"2009"},{"key":"10.1038\/ki.2011.142_bb0175","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1038\/ki.2011.142_bb0180","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0185","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0190","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0195","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0200","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1038\/ki.2011.142_bb0205","first-page":"1972","volume":"119","author":"Jessep","year":"2009","journal-title":"Circulation"},{"key":"10.1038\/ki.2011.142_bb0210","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0215","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0000605-200912150-00162","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease","volume":"151","author":"Baker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2011.142_bb0220","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041552-200105000-00005","article-title":"Pro-inflammatory actions of angiotensins","volume":"10","author":"Ruiz-Ortega","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2011.142_bb0230","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"68","author":"Remuzzi","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.142_bb0235","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0240","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE Study and MICRO-HOPE Sub-Study","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0245","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0250","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0255","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0260","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1038\/ki.2011.142_bb0265","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2011.142_bb0270","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type i diabetic patients with diabetic nephropathy","volume":"l4","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_rf0275","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.142_bb0280","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabetes Med"},{"key":"10.1038\/ki.2011.142_bb0285","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1038\/ki.2011.142_bb0290","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.142_bb0295","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0300","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0305","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jacc.2009.02.074","article-title":"Dual renin-angiotensin system blockade and kidney disease","volume":"54","author":"Parving","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2011.142_bb0310","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ndt\/gfp633","article-title":"ONTARGET should not be over interpreted","volume":"25","author":"Abutaleb","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.142_bb0315","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrneph.2009.109","article-title":"Proteinuria: Is the ONTARGET renal substudy actually off target?","volume":"5","author":"Ruggenenti","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1038\/ki.2011.142_bb0320","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1681\/ASN.2004060447","article-title":"Performance of the modification of diet in renal disease and Cockcroft-Gault study equations in the estimation of GFR in health and in chronic kidney disease","volume":"16","author":"Poggio","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-141-12-200412210-00009","article-title":"Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease","volume":"141","author":"Rule","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2011.142_bb0330","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1038\/ki.2011.142_bb0335","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1681\/ASN.2007080837","article-title":"Acute kidney injury increases risk of ESRD among elderly","volume":"20","author":"Ishani","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0340","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0345","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jama.299.12.1474","article-title":"Surrogate end points and FDA approval. A tale of 2 lipid-altering drugs","volume":"299","author":"Psaty","year":"2008","journal-title":"JAMA"},{"key":"10.1038\/ki.2011.142_bb0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA's accelerated approval process","volume":"24","author":"Fleming","year":"2005","journal-title":"Health Affairs"},{"key":"10.1038\/ki.2011.142_bb0355","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2006.06.005","article-title":"Microalbuminuria","volume":"26","author":"Khosla","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1038\/ki.2011.142_bb0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000313553","article-title":"Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?","volume":"31","author":"Glassock","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.142_bb0365","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000292500","article-title":"Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?","volume":"31","author":"Weir","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.142_bb0370","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0375","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Combination angiotensin receptor blockers and angiotensin converting enzyme inhibitor for the treatment of diabetic nephropathy VA Nephron-D study","volume":"4","author":"Freid","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0380","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design","volume":"5","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.142_bb0385","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semnephrol.2004.01.003","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy","volume":"24","author":"Dillon","year":"2004","journal-title":"Sem Nephrol"},{"key":"10.1038\/ki.2011.142_bb0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","article-title":"Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy","volume":"38","author":"Russo","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0395","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000065227","article-title":"Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis","volume":"22","author":"Tylicki","year":"2002","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.142_bb0400","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.ajkd.2003.10.032","article-title":"Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis","volume":"43","author":"Rutkowski","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0405","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0410","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000098196","article-title":"Controversy about COOPERATE ABPM trial data. Letter to the Editor","volume":"26","author":"Bidani","year":"2006","journal-title":"Am J Nephrol"},{"key":"10.1038\/ki.2011.142_bb0415","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(08)60681-9","article-title":"The COOPERATE trial: a letter of concern","volume":"371","author":"Kunz","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.142_bb0420","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0425","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2011.142_bb0430","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT Polycystic kidney disease trials. Design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0435","first-page":"646","article-title":"LIRICO study group. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial","volume":"20","author":"Maione","year":"2007","journal-title":"J Nephrol"},{"key":"10.1038\/ki.2011.142_bb0440","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/ndt\/gfn239","article-title":"Maximizing inhibition of the renin-angiotensin system with high dose of converting enzyme inhibitors or angiotensin receptor blockers","volume":"23","author":"Berl","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.142_bb0445","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benezapril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0450","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"A double-blind randomized controlled trial of high dose candesartan cilexetil in proteinuria renal disease results from SMART (Supra maximal atacand renal trial)","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0455","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities","volume":"16","author":"Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0460","series-title":"Am Coll Cardiol","article-title":"Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction: ASPIRE","author":"Solomon","year":"2010"},{"key":"10.1038\/ki.2011.142_bb0465","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0470","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ki.1989.259","article-title":"Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis","volume":"36","author":"Alfrey","year":"1989","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.142_bb0475","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMoa021672","article-title":"Environmental lead exposure and progression of chronic renal disease in patients without diabetes","volume":"348","author":"Lin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2011.142_bb0480","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0485","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2008.07.021","article-title":"Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and\/or diuretics on urinary kidney injury molecule 1 excretion in non diabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial","volume":"53","author":"Waandeis","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0490","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2215\/CJN.03530708","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.142_bb0495","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfm541","article-title":"Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients","volume":"23","author":"Bolignano","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2011.142_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2008.11.002","article-title":"Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression","volume":"53","author":"Perico","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.142_bb0505","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lab.2004.12.003","article-title":"Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial","volume":"145","author":"Kamijo","year":"2005","journal-title":"J Lab Clin Med"},{"key":"10.1038\/ki.2011.142_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2006.05.038","article-title":"Urinary fatty acid binding protein in renal disease","volume":"374","author":"Kamijo-Ikemori","year":"2006","journal-title":"Clin Chim Acta"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815550357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815550357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T10:07:24Z","timestamp":1560247644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815550357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0085253815550357"],"URL":"https:\/\/doi.org\/10.1038\/ki.2011.142","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}